New cholesterol combo drugs enter human testing

NCT ID NCT07162441

Recruiting now Knowledge-focused Sponsor: Korea United Pharm. Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial is testing two experimental drugs for high cholesterol, called UIC202502 and UIC202505, in 50 healthy adults. The goal is to see how the drugs interact when taken together or alone, and to check for safety. Participants will take each drug separately and then both together over several weeks. This study does not test whether the drugs actually lower cholesterol.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UIC202502 and UIC202505 (experimental drugs for high cholesterol)
What this could lead to: If successful, this study could help determine safe dosing for future trials of these drugs for high cholesterol.
What could go wrong: This is a very early Phase 1 study in healthy volunteers, not patients. It only looks at drug interaction and safety, not whether the drugs actually treat high cholesterol.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDEMIA

Contacts and locations

Locations

H plus Yangji Hospital
RECRUITING

Seoul, Gwanak-gu, 08779, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.